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Open access under CC BY-NC-ND license.BACKGROUND & AIMS: Neutrophils can either promote or
inhibit tumor progression, depending on the tumor microenvi-
ronment, via release of cytokines. Neither the factors produced
by tumor-associated neutrophils (TANs) nor their effects on
tumor progression have been characterized. We investigated the
roles of TANs in progression of hepatocellular carcinoma (HCC)
using cell lines and immune cells isolated from patients.
METHODS: We performed studies with HepG2, PLC/PRF/5,
MHCC97H, and HCCLM3 human and Hepa1-6 and H22 mouse
HCC cell lines; expression of chemokines and cytokines were
knocked down with small hairpin RNAs. Cells were analyzed in
chemotaxis assays and as growth as tumors in mice. HCC tissues
and peripheral blood were collected from 20 patients under-
going curative resection or 20 healthy individuals (controls) in
2012 at Zhongshan Hospital in China. TANs and peripheral
blood neutrophils (PBNs) were isolated and exposed to condi-
tioned media from HCC cell lines; reverse-transcription poly-
merase chain reaction was used to quantify the expression of
cytokines and chemokines. We collected neutrophils from
another 60 patients undergoing curative resection for HCC in
2012 to measure the production of C-C motif chemokine ligand
2(CCL2) and CCL17. Patients were followed up until March 15,
2014. For immunohistochemical analyses, we collected HCC
tissues and paired, adjacent, nontumor cirrhotic liver tissues
from 832 HCC patients undergoing curative resection from 2006
through 2008. All patients were followed up until March 15,
2013. To study the effects of sorafenib, we collected clinical and
pathology data from 46 patients who underwent curative
resection in 2010. RESULTS: CCL2 and CCL17 were the cyto-
kines most highly expressed by TANs and HCC cell-activated
PBNs. Levels of CCL2 and CCL17 messenger RNAs and proteins
were signiﬁcantly higher in TANs than in PBNs, and increased in
patients with HCC recurrence. CCL2 and CCL17 messenger RNA
and proteins also increased when PBNs were exposed to
conditioned media from HCC cell lines. Immunohistochemical
analysis of a tissue microarray showed that CCL2þ and CCL17þ
cells, which also expressed the neutrophil marker CD66b, were
distributed throughout the HCC stroma, but not in tumor cells or
the adjacent nontumor liver cells. The number of CCL2þ or
CCL17þ TANs correlated with tumor size, microvascular inva-
sion, tumor encapsulation, tumor differentiation, and stage. Pa-
tients whose tumors had lower levels of CCL2þ or CCL17þ cells
had longer survival times than those with higher numbers of
these cells. TAN-conditioned media, as well as recombinant
CCL2 and CCL17, increased the migratory activity of themacrophages and T-regulatory (Treg) cells from patients or mice
with HCC to a greater extent that PBN-conditioned media.
Neutralizing antibodies against CCL2 and CCL17, or their re-
ceptors C-C chemokine receptor 2 and C-C chemokine receptor 4,
reduced the migratory activities of macrophage and Treg cells.
HCC cell lines injected into mice formed larger tumors when they
were co-injected with TANs and formed more pulmonary me-
tastases; these tumors were inﬁltrated by Ly6Gþ cells, F4/80þ
macrophages, and Foxp3þ Treg cells. In a phosphokinase array
of human PBNs, levels of phosphorylated AKT and P38 increased
after exposure to conditioned media from all 4 HCC cell types.
Pharmacologic inhibitors of AKT and P38 inhibited secretion of
CCL2 and CCL17 by these PBNs. In tumor-bearingmice, sorafenib
increased the numbers of TANs and levels of CCL2 and CCL17 in
tumors. HCC tissues from patients who received sorafenib before
surgery containedmore TANs than tissues from patients who did
not receive sorafenib. In knockdown cells, HCC cell–derived
CXCL5 was the strongest effector of neutrophil migration under
hypoxic conditions. In mice, the combination of sorafenib and
TAN depletion inhibited tumor growth and neovascularization to
a greater extent than sorafenib alone. CONCLUSIONS: TANs re-
cruit macrophages and Treg cells to HCCs to promote their
growth, progression, and resistance to sorafenib.
Keywords: Liver Cancer; Mouse Model; Immune Response;
Neovascularization.
ancers rely on the tumor microenvironment, whichCcomprises a variety of nonmalignant stromal cells
for growth, invasion, and metastasis.1,2 Recent evidence has
indicated that there is a complex and multidirectional
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stromal cells during cancer development and progression.
The interaction between tumor and stromal cells may
polarize stromal cells to favor tumor promotion.2,3 More-
over, unlike tumor cells, stromal cells within the tumor
microenvironment are genetically stable and represent an
attractive therapeutic target because they are less likely to
develop drug resistance.2
Recently, there has been emerging interest to study the
role of neutrophils in cancer. This interest stems from
the fact that cancer-related inﬂammation now is recog-
nized as a new hallmark of cancer.4 In the tumor micro-
environment, tumor-associated neutrophils (TANs) have
been proposed to support tumor development by pro-
moting cellular transformation, tumor progression, and
antitumor immunity.5 TAN inﬁltration is prognostic in
several human cancers,6 including hepatocellular carci-
noma (HCC).7 Neutrophils may inﬂuence tumor progres-
sion through the paracrine release of cytokines and
chemokines with protumor or antitumor functions,
depending on the tumor microenvironment.8 Until now, a
full characterization of the factors released by TANs has
not been performed, and it is unclear whether there are
factors released exclusively by TANs that drive tumor
progression. Moreover, the role of TANs in HCC progres-
sion and their effect on the microenvironment remain
undeﬁned.
A multikinase inhibitor called sorafenib is the only drug
that is approved to treat patients with advanced HCC.9
Sorafenib inhibits Raf, as well as the kinase activity of
vascular endothelial growth factor receptor and platelet-
derived growth factor receptor.10 Despite an apparent sur-
vival beneﬁt, the response rate to sorafenib is low, with only
a modest prolongation of survival.11 Therefore, it is crucial
to identify the molecular mechanisms mediating sorafenib
resistance to improve clinical outcomes for HCC patients.
We designed this study to examine the role of TANs in
the progression of HCC, particularly to uncover their effects
on the tumor microenvironment. We also tested the role of
TANs in sorafenib resistance. Finally, we validated our re-
sults in clinical HCC samples.Materials and Methods
Cell Lines, Animals, and Lentiviral Vectors
Four human and 2 mouse HCC cell lines were used in
this investigation. MHCC97H and HCCLM3 (highly meta-
static human HCC cell lines) were established at our
institute.7 HepG2, PLC/PRF/5 (low-metastatic human HCC
cell lines; American Type Culture Collection, Manassas, VA),
Hepa1-6, and H22 (mouse HCC cell lines) were procured
through the Institute of Biochemistry and Cell Biology
(Chinese Academy of Sciences, Shanghai, China) and
transfected with pGCSIL-Green Fluorescent Protein (GFP)
lentiviral vectors. These cell lines all routinely were
maintained. For experiments under hypoxic conditions,
cells were exposed to 1% O2 in an InvivO2 200 hypoxia
chamber (Ruskinn Technologies, Leeds, UK). Male C57BL/6
and BALB/c mice (4–6 weeks old, obtained from theShanghai Institute of Material Medicine, Chinese Academy
of Science) were housed in pathogen-free conditions. All
animals received humane care according to the criteria
outlined in the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health publication 86-23,
revised 1985).
The pGCSIL–GFP–short hairpin RNA (shRNA)–hypoxia-
inducible factor 1 (HIF1)a/p65/CXCL5/CXCL16/CCL24/inter-
leukin 12a lentiviral vectors were procured from Shanghai
GeneChem Co (Shanghai, China), and the target shRNA se-
quences are listed in Supplementary Table 1. pGCSIL-GFP len-
tiviral vectors were used as controls. Transduction was
performed as previously described.7
Patients and Follow-Up Evaluation
For neutrophil isolation and RT2 proﬁler polymerase
chain reaction (PCR) array analysis, tumor tissues and pe-
ripheral blood from 20 HCC patients undergoing curative
resection in February 2012 and peripheral blood from 20
healthy donors who had a medical check-up during the same
period in Zhongshan Hospital were collected. For examina-
tion of CCL2 and CCL17 expression on neutrophils, another
set of 60 HCC patients undergoing curative resection be-
tween February and March of 2012 were collected. All of
these patients were monitored postsurgically until March
15, 2014.
For immunohistochemical and prognostic analysis, 2
independent cohorts totaling 832 HCC patients were
enrolled (Supplementary Table 2). The 452 tumor tissues
and paired adjacent nontumor cirrhotic liver tissues were
obtained from patients undergoing curative resection be-
tween 2007 and 2008 at the Liver Cancer Institute,
Zhongshan Hospital, Fudan University (cohort 1, snap-
frozen tissues and corresponding parafﬁn-embedded tis-
sues). In the other cohort, parafﬁn-embedded tissues were
obtained randomly from HCC patients undergoing curative
resection in 2006 (cohort 2, n ¼ 380). All patients were
monitored postsurgically until March 15, 2013. The histo-
pathologic diagnosis was based on the World Health Orga-
nization criteria. The tumor grade was determined in
accordance with the classiﬁcation proposed by Edmondson
and Steiner.12 The Child–Pugh scoring system was used to
assess liver function. Tumor stage was determined accord-
ing to the TNM classiﬁcation system established by the
2010 International Union Against Cancer. The Research
Ethics Committee of Zhongshan Hospital approved the
ethical use of human subjects for this study, and informed
consent was obtained from each patient. Postsurgical pa-
tient surveillance was performed as previously
described.13,14 Overall survival was deﬁned as the interval
between surgery and death or between surgery and the last
observation point. For surviving patients, the data were
censored at the last follow-up evaluation. Time to recur-
rence15 was deﬁned as the interval between the surgery
date and the date of any diagnosed relapse (intrahepatic
recurrence and extrahepatic metastasis).
For patients enrolled in the sorafenib study, 46 patients
who underwent curative resection in 2010 at the Liver Cancer
Institute were included, and these patients received sorafenib
treatment after recurrence. Clinical and pathologic data were
collected (Supplementary Tables 3 and 4), and all of these
Figure 1. HCC TANs ex-
press high levels of CCL2
and CCL17. (A) The ratio
(>2.0) of a panel of cyto-
kine/chemokine mRNAs in
TANs vs PBNs from pa-
tients with HCC (pPBNs)
and (B) HCC cell-activated
PBNs vs unactivated
PBNs from healthy donors
(nPBNs). (C) Quantitative
reverse-transcription poly-
merase chain reaction and
enzyme-linked immuno-
sorbent assay for CCL2
and CCL17 in TANs, paired
pPBNs, and nPBNs. (D)
Western blot for CCL2
and CCL17 in TANs (T)
and paired pPBNs (P)
from HCC patients with
or without recurrence.
(E) Immunohistochemical
staining of CD66b, CCL2,
and CCL17 in HCC. Scale
bar: 100 mm. (F) Kaplan–
Meier survival curve of
HCC patients with lower
(<12 per view of ﬁeld, n ¼
226) and higher TAN
counts (12 per view of
ﬁeld, n ¼ 226), or with
lower (<8 per view of ﬁeld,
n ¼ 227) and higher CCL2-
positive TAN counts (8
per view of ﬁeld, n ¼ 225),
or with lower (<9 per view
of ﬁeld, n¼ 229) and higher
CCL17-positive TAN
counts (9 per view of
ﬁeld, n ¼ 223). BMP, bone
morphogenetic protein;
GAPDH, glyceraldehyde-3-
phosphate dehydroge-
nase; HR, hazard ratio; IL,
interleukin; TGF, trans-
forming growth factor;
VEGF, vascular endothelial
growth factor.
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In the patients who received sorafenib treatment before sur-
gical intervention, an oral dose of 0.4 g was taken twice daily,
and these patients typically stopped taking oral sorafenib 3
days before surgical resection.
Additional information is available in the Supplementary
Materials and Methods section.Results
CCL2 and CCL17 Expression in HCC-Associated
TANs Is Correlated With Tumor Progression
and Prognosis
To identify the factors secreted exclusively by TANs
in HCC, we used a PCR array to quantify the expression of a
Table 1.Univariate and Multivariate Analyses of Prognostic Factors in HCC: Cohort 1 (n ¼ 452)
Variable
TTR OS
HR (95% CI) P HR (95% CI) P
Univariate analysis
Age, y, 50 vs >50 1.10 (0.86–1.42) .444 1.26 (0.96–1.66) .091
Sex, female vs male 1.21 (0.84–1.72) .306 1.50 (1.00–2.26) .052
HBsAg, negative vs positive 1.06 (0.76–1.49) .717 1.12 (0.78–1.62) .536
AFP level, ng/mL, 20 vs >20 1.32 (1.02–1.70) .035 1.77 (1.33–2.36) .000
GGT level, U/L, 54 vs >54 1.68 (1.29–2.18) .000 1.82 (1.37–2.42) .000
Cirrhosis, no vs yes 1.10 (0.68–1.80) .024 1.78 (1.17–2.73) .007
Tumor size, cm, 5 vs>5 1.71 (1.33–2.20) .000 2.37 (1.79–3.13) .000
Tumor number, single vs multiple 1.19 (0.84–1.68) .333 0.99 (0.67–1.46) .961
Microvascular invasion, no vs yes 1.71 (1.33–2.20) .000 2.20 (1.69–2.87) .000
Tumor encapsulation, complete vs none 1.47 (1.14–1.88) .002 1.91 (1.46–2.51) .000
Tumor differentiation, IþII vs IIIþIV 1.61 (1.25–2.08) .000 1.79 (1.37–2.35) .000
TNM stage, I vs II III 1.62 (1.26–2.07) .000 1.99 (1.53–2.60) .000
CD66b, low vs high 1.95 (1.52–2.51) .000 2.19 (1.66–2.88) .000
CCL2, low vs high 2.09 (1.62–2.69) .000 2.59 (1.97–3.42) .000
CCL17, low vs high 2.26 (1.75–2.91) .000 2.91 (2.20–3.85) .000
Multivariate analysis
AFP, ng/mL, 20 vs >20 1.19 (0.92–1.55) .192 1.52 (1.13–2.03) .006
GGT, U/L, 54 vs >54 1.44 (1.09–1.90) .011 1.38 (1.02–1.88) .037
Cirrhosis, no vs yes 1.46 (1.01–2.13) .047 1.70 (1.10–2.62) .018
Tumor size, cm, 5 vs >5 1.42 (1.09–1.87) .011 1.96 (1.46–2.65) .000
Microvascular invasion, no vs yes 1.29 (0.98–1.68) .065 1.45 (1.10–1.93) .009
Tumor encapsulation, complete vs none 1.29 (1.00–1.66) .050 1.54 (1.17–2.04) .002
Tumor differentiation, IþII vs IIIþIV 1.34 (1.03–1.74) .030 1.42 (1.08–1.87) .012
CD66b, low vs high 1.86 (1.44–2.40) .000 2.06 (1.56–2.72) .000
CCL2, low vs high 2.06 (1.59–2.66) .000 2.54 (1.92–3.37) .000
CCL17, low vs high 2.10 (1.62–2.72) .000 2.60 (1.96–3.46) .000
NOTE. Cox proportional hazards regression model. The boldfaced numerals indicates P value <.05.
AFP, a-fetoprotein; CI, conﬁdence interval; GGT, g glutamyltransferase; HBsAg, hepatitis B antigen; HR, hazard ratio;
OS, overall survival; TTR, time to recurrence.
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paired TAN and peripheral blood neutrophil (PBN) samples
isolated from 20 HCC patients (pPBNs), as well as PBNs
obtained from 20 healthy donors (normal PBNs [nPBNs])
that were either treated or untreated with conditioned
media from HCC cell lines (HepG2, PLC/PRF/5, MHCC97H,
HCCLM3). TANs and HCC cell-activated nPBNs had compa-
rable cytokine and chemokine messenger RNA (mRNA)
proﬁles. Of all the factors evaluated, CCL2 and CCL17 were
the most abundantly expressed chemokines in both TANs
and HCC cell-activated nPBNs (Figure 1A and B).
To conﬁrm the expression of CCL2 and CCL17 in HCC-
associated TANs, we examined the mRNA and protein
levels of these chemokines in paired TANs and pPBN sam-
ples isolated from an additional 60 HCC patients and in
nPBN samples isolated from 60 healthy donors. CCL2 and
CCL17 mRNA were signiﬁcantly higher in TANs than in
pPBNs or in nPBNs, and even higher in patients with HCC
recurrence (Figure 1C and Supplementary Figure 1A).
Western blot and enzyme-linked immunosorbent assay
conﬁrmed the abundant expression of both CCL2 and CCL17
in TANs (Figure 1C and D) and on patients with HCC
recurrence (Figure 1D and Supplementary Figure 1B) at the
protein level. Similarly, CCL2 and CCL17 mRNA and protein
were up-regulated considerably in HCC cell-activatednPBNs, but were not detected in untreated nPBNs or HCC
cells (Supplementary Figure 1C–F).
Immunohistochemistry of a tissue microarray for
CCL2 and CCL17 expression in HCC tissues showed that
CCL2- and CCL17-positive cells were distributed throughout
the tumor stroma (Figure 1E). However, there was no staining
in the tumor cells or the adjacent nontumor liver cells. We
noted a signiﬁcant positive correlation between cells
expressing the CD66b neutrophil marker and CCL2 or CCL17
(Supplementary Figure 1G and H). Furthermore, CCL2 or
CCL17 and CD66b co-localized in immunostaining in TANs by
confocal microscopy, conﬁrming that TANs preferentially
expressed CCL2 and CCL17 (Supplementary Figure 1I and J).
We next correlated the number of CCL2þ and CCL17þ
TANs with the clinicopathologic status and prognosis of
patients with HCC. The number of CCL2þ or CCL17þ TANs
was correlated signiﬁcantly with tumor size, microvascular
invasion, tumor encapsulation, tumor differentiation, and
TNM stage (Supplementary Table 5). Patients in the CCL2þ
TANLow or CCL17þ TANLow groups had signiﬁcantly better
outcomes than those in the CCL2þ TANHigh or CCL17þ
TANHigh group (Figure 1F). Univariate and multivariate an-
alyses showed that the presence of CD66bþ, CCL2þ, or
CCL17þ neutrophils was an independent prognostic indi-
cator for HCC (Table 1).
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Figure 2. TANs recruit macrophages and Treg cells to facilitate HCC neovascularization and progression through CCL2 and
CCL17. (A) Culture media from HCC patient TANs or (B) tumor-bearing mice increased the migration of macrophages and Treg
cells more than PBNs, and this recruitment was abrogated by blockade of CCL2 or CCR2 and CCL17 or CCR4. *P < .05 and
**P < .01 compared with control; #P < .05 when compared with TANs þ control antibody (Ab). (C) TANs signiﬁcantly increased
the tumor volume and pulmonary metastasis rates in mouse models, and this effect was abrogated completely after depletion
of TANs and signiﬁcantly impaired by intratumoral injection with anti-CCL2 and anti-CCL17 antibodies. *P < .05 and **P < .01
compared with control; #P < .05 and ##P < .01 when compared with TANs þ control Ab. (D) TANs increased intratumoral F4/
80þ macrophages and Foxp3þ Treg cell inﬁltration and MVD in mouse models. **P < .01. Scale bars: 50 mm.
Figure 3. HCC cells educated nPBNs to gain TAN-like characteristics through PI3K/Akt and p38/MAPK signaling. (A) Signaling
pathways activated by HCC cells in nPBNs were screened by probing a human phosphokinase array with lysates from control
conditioned media (CM)-treated human nPBNs or HCC cell line-derived CM. (B) Western blot to validate the expression of
proteins with increased phosphorylation upon HCC cell line-derived CM treatment. (C and D) Western blot and enzyme-linked
immunosorbent assay showed that blocking both pathways by using LY294002 and SB203580 completely inhibited the
increased secretion of CCL2 and CCL17. (E) Co-injection of nPBNs with HCC cells resulted in increased tumor growth and
pulmonary metastasis than injection of tumor cells alone in mouse models. *P < .05. Scale bars: 100 mm. Con, control; DMSO,
dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LY, LY294002; SB, SB203580.
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Cells Through CCL2–C-C Chemokine Receptor 2
and CCL17–C-C Chemokine Receptor 4
CCL2 and CCL17 can recruit C-C chemokine receptor 2
(CCR2)þ inﬂammatory monocytes/macrophages, and
CCR4þ T-regulatory (Treg) cells.16,17 We conﬁrmed thatrecombinant human CCL2 and CCL17 preferentially recruit
macrophages and Treg cells from HCC patients. Further-
more, this response was abrogated by treatment with anti-
CCL2 or anti-CCL17 antibodies, and was attenuated
signiﬁcantly by treatment with anti-CCR2 or anti-CCR4
antibodies (Supplementary Figure 2A). Next, we tested
June 2016 TANs in HCC and Sorafenib Resistance 1653whether TANs recruit human macrophages and/or Treg
cells in vitro through CCL2 or CCL17. As shown in
Figure 2A, TAN-conditioned media increased the migratory
activity of the macrophages and Treg cells more than PBN-
conditioned media. Furthermore, anti-human CCL2 or
CCL17 neutralizing antibodies signiﬁcantly inhibited the
enhanced macrophage and Treg cell migratory activity,
respectively (Figure 2A), but did not affect the modest
migration induced by pPBNs or nPBNs (Supplementary
Figure 2B and C). Antibodies speciﬁc for human CCR2
and CCR4 had the same effect (Figure 2A and
Supplementary Figure 2B and C). In addition, we conﬁrmed
these results using mouse HCC cells (Figure 2B and
Supplementary Figure 2D–F).BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
RTANs Promote Intratumoral Inﬁltration by
Macrophages and Treg Cells and Facilitate
HCC Neovascularization and Progression
in a Mouse Model
To investigate the inﬂuence of TANs on tumor growth and
metastasis, we designed an in vivo mouse model
(Supplementary Figure 3A). Tumor volume increased signif-
icantly when HCC cells were co-injected with TANs compared
with HCC cells alone (Figure 2C). Moreover, the pulmonary
metastasis rate also was greater in this group (Figure 2C).
Immunohistochemical analysis showed abundant Ly6Gþ cell
inﬁltration and increased F4/80þ macrophages and Foxp3þ
Treg cells in tumor tissues derived from the co-injection of
HCC cells and TANs, suggesting that TANs can promote the
intratumoral inﬁltration of these cells in vivo (Figure 2D).
Because neutrophils, macrophages, and Treg cells can induce
tumor vascularization,18,19 we tested whether the inﬁltration
of these cells altered the tumor microvascular density (MVD).
Immunostaining for CD34, an endothelial cell marker,
showed that MVD was increased signiﬁcantly in tumor tis-
sues derived from the co-injection of HCC cells with TANs,
and was abrogated when TANs were depleted by using an
anti-Ly6G antibody. MVD also was attenuated signiﬁcantly by
treatment with anti-CCL2 and anti-CCL17 antibodies, which
depleted intratumoral macrophages and Treg cells (Figure 2D
and Supplementary Figure 3B). The depletion of these cells
also signiﬁcantly attenuated the protumor effect driven by
TAN co-injection (Figure 2C).=
Figure 4. Sorafenib treatment increased the intratumoral inﬁltr
intratumoral neutrophil inﬁltration in mouse HCC models. **P
hepatic surgery induced more intratumoral neutrophil inﬁltration
merase chain reaction array identiﬁed 4 cytokines/chemokines t
were validated by enzyme-linked immunosorbent assay (right).
that CXCL5 knockdown abolished hypoxia-induced neutrophil m
and p65 nuclear accumulation under hypoxia, and enhanced N
assay. *P < .05, **P < .01. (E) Western blot for CXCL5 in hyp
shRNA-HIF1a, or shRNA-p65, or pretreated with dimethyl sulfo
the apoptosis of nPBNs, pPBNs, and TANs (Un) as measured by
for caspase-3, TANs (Un), TANs from HCC patients who were
tients who were treated with sorafenib. *P < .05, **P < .01. CM,
phosphate dehydrogenase.HCC Cells Educate Normal PBNs to Become
TAN-Like and Express CCL2 and CCL17
Through the Induction of Phosphoinositide
3 Kinase/Akt and p38/Mitogen-Activated
Protein Kinase Signaling
In response to HCC cells, nPBNs secreted more cytokines
and chemokines, particularly CCL2 and CCL17, and gained
the characteristics of TANs. Thus, we aimed to explore the
mechanism by which HCC cells educated nPBNs to become
TAN-like. We analyzed a phosphokinase array on human
nPBNs cultured with or without HCC cell-conditioned media
to determine the kinase proﬁle of several distinct signaling
pathways. We found that p-AKTSer473 and p-P38T180/Y182
were up-regulated in nPBNs more than 100% in response to
conditioned media from 4 HCC cell types (Figure 3A and
Supplementary Figure 4). These data were validated by
Western blot (Figure 3B). Next, we found that blocking the
phosphoinositide 3 kinase (PI3K)/Akt and p38/mitogen-
activated protein kinase (MAPK) pathways by using
LY294002 and SB203580, respectively, completely inhibited
the increased secretion of CCL2 and CCL17, suggesting that
HCC-driven education of nPBNs requires these signaling
pathways (Figure 3C and D and Supplementary
Figure 5A–C). Furthermore, our in vivo study showed that
co-injection of nPBNs with HCC cells resulted in increased
tumor growth and pulmonary metastasis that, although
slower than that of HCC cells mixed with TANs, was
signiﬁcantly greater than that of tumor cells alone
(Figure 3E). This observation supports the notion that
nPBNs can be educated by HCC cells in vivo.Sorafenib Treatment Increases TAN Inﬁltration
in Animal Models and HCC Patients
We examined TAN inﬁltration of tumor tissue in
response to sorafenib treatment in mouse HCC models. TAN
inﬁltration was increased signiﬁcantly in response to sor-
afenib treatment (Figure 4A, left panel) and was accompa-
nied by increased levels of secreted CCL2 and CCL17 in
these tumor tissues (Supplementary Figure 6A). In HCC
patients who received sorafenib treatment before hepatic
surgery, more TAN inﬁltration was observed than in those
who received no treatment (Figure 4A, right panel).
Considered together, these data suggest that sorafenib mayation of neutrophils. (A) Left: sorafenib treatment increased
< .01. Scale bars: 50 mm. Right: sorafenib treatment before
in HCC patients. **P < .01. Scale bars: 100 mm. (B) A poly-
hat increased upon hypoxia in all 4 HCC cell lines (left), which
(C) shRNA and an in vitro Transwell migration assay showed
igration. **P < .01. (D) Western blot showed increased HIF1a
F-kB DNA binding activity by enzyme-linked immunosorbent
oxia-treated HCC cell lines pretransfected with shRNA-NC,
xide (DMSO), BAY-117082, or JSH-23. (F) Hypoxia inhibited
annexin V/propidium iodide (AV/PI) staining and Western blot
not treated with sorafenib; TANs (Sora), TANs from HCC pa-
conditioned media; Con, control; GAPDH, glyceraldehyde-3-
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Although our study showed that sorafenib directly inhibits
p38/MAPK signaling in nPBNs, this effect was weak
(Supplementary Figure 7A and B), and p38/MAPK signaling
still was activated signiﬁcantly in response to HCC cells
(Supplementary Figure 7C–H).
Sorafenib Treatment Induces TAN Recruitment
by Inducing CXCL5 Expression in HCC Cells via
the HIF1a/Nuclear Factor-kB Pathway
It is widely accepted that hypoxia caused by anti-
angiogenic therapy contributes to therapy resistance in
solid tumors. Thus, we hypothesized that hypoxia induced
by sorafenib treatment may increase cytokine and che-
mokine secretion by HCC cells, leading to the consequent
recruitment of neutrophils into the tumor. To conﬁrm
this hypothesis, we used the cytokine/chemokine PCR
array to screen HCC cells under hypoxic vs normoxic
conditions, and identiﬁed 4 factors that were increased
upon exposure to hypoxia (Figure 4B and Supplementary
Figure 6B). By using shRNA and an in vitro Transwell
(Corning, Corning, NY) migration assay, we identiﬁed HCC
cell-derived CXCL5 as the strongest effector of neutrophil
migration under hypoxic conditions (Figure 4C and
Supplementary Figure 6B).
It has been reported that the p65 subunit of nuclear
factor-kB (NF-kB) can regulate CXCL5 gene expression and
can be activated by hypoxia.20,21 We found that hypoxia
induced both HIF1a and p65 nuclear accumulation and
enhanced NF-kB DNA binding activity (Figure 4D and
Supplementary Figure 6C and D), indicating activation of
the HIF1a/NF-kB pathway. Inhibition of NF-kB by BAY-
117082 (an IKK inhibitor), 4-methyl-N1-(3-phenyl-
propyl)-benzene-1,2-diamine (JSH-23, an inhibitor of
NF-kB nuclear translocation), or knockdown of HIF1a or
p65 reversed the hypoxia-induced expression of CXCL5 by
HCC cells (Figure 4E and Supplementary Figure 6E).
Moreover, we observed increased nuclear expression of
HIF1a and p65 in sorafenib-treated HCC-bearing mouse
models and patients, accompanied by increased CXCL5
expression (Supplementary Figure 6G). We also observed
that during sorafenib treatment, TAN inﬁltration was
correlated strongly with HIF1a expression (Supplementary
Figure 6F), indicating that sorafenib-induced hypoxia in-
duces TAN recruitment via the HIF1a/NF-kB/CXCL5
pathway.Hypoxia Induced by Sorafenib Inhibits the
Apoptosis of TANs
As short-lived effector cells, neutrophils circulate in the
bloodstream after leaving the bone marrow, at which point
they undergo spontaneous apoptosis.22 The tumor micro-
environment can promote neutrophil survival,23 which we
conﬁrmed by showing that apoptosis was decreased
signiﬁcantly in TANs as compared with matched pPBNs or
nPBNs, and was decreased further in TANs from patients
who received sorafenib (Figure 4F). Moreover, we observedthat hypoxia can inhibit the apoptosis of nearly all types of
neutrophils, except those from HCC patients receiving
sorafenib treatment (Figure 4F). We also validated these
results in mouse H22 and Hepa1-6 cell-bearing models
(Supplementary Figure 6H), which strongly suggested
that hypoxia induced by sorafenib inhibited the apoptosis
of TANs.
TAN Depletion Inhibits Tumor Growth and
Angiogenesis When Combined With Sorafenib
We tested the effect of combined treatment with an
anti-Ly6G antibody, which depletes TANs, and sorafenib in
mouse HCC models. As shown in Figure 5A, sorafenib-
treated mice had a smaller tumor volume as compared
with control mice. Combination treatment with sorafenib
and an anti-Ly6G antibody lead to a further reduction in
tumor volume. Meanwhile, accompanied with increased
TAN accumulation, we observed more intratumoral
macrophage and Treg cell inﬁltration in tumor tissues, and
all these cells were reduced after anti-Ly6G antibody
treatment (Supplementary Figure 8). In addition, sor-
afenib signiﬁcantly inhibited tumor angiogenesis, as indi-
cated by reduced MVD in HCC models, and sorafenib
combined with TAN depletion further inhibited tumor
angiogenesis (Figure 5B).
TAN Inﬁltration Is Correlated With the Number of
Intratumoral Macrophages and Treg Cells, MVD,
Prognosis, and the Response to Sorafenib in
HCC Patients
We immunostained a tissue microarray from 452 HCC
patients to quantify the number of intratumoral TANs,
macrophages (CD68þ), and Treg cells (Foxp3þ). We
observed a signiﬁcant correlation between the number of
inﬁltrative TANs and intratumoral macrophages, especially
M2 tumor-associated macrophages (CD163þ or CD206þ),
and Treg cells (Figure 6A and C and Supplementary
Figure 9). Furthermore, the inﬁltration of these cells was
well correlated with MVD (Figure 6B), and predicted prog-
nosis (Supplementary Figure 10). When the 3 cell types
were combined, we observed a more signiﬁcant correlation
with MVD and a greater sensitivity for predicting the
prognosis of HCC patients (Figure 6D and E). In addition,
these results were validated in an independent cohort of
380 HCC patients (Supplementary Figure 11 and
Supplementary Tables 6 and 7).
We also included retrospective data from 46 advanced
recurrent HCC patients who received sorafenib treatment
after undergoing liver resection. Sorafenib prolonged sur-
vival only in patients whose tumors had low TAN inﬁltration
(Figure 6F). Thus, we concluded that a high number of TANs
leads to sorafenib resistance in HCC.
Discussion
Mounting evidence has emerged suggesting that TANs
are an essential component of the tumor microenvironment
and play a role in tumor progression, and, therefore, need to
Figure 5. Depletion of TANs inhibited tumor growth and
angiogenesis when combined with sorafenib. (A) Sorafenib or
combination treatment with sorafenib and an anti-Ly6G
antibody inhibited tumor growth in mouse HCC models.
*P < .05 compared with control. #P < .05 and ##P < .01 when
compared with sorafenib þ control antibody (Ab).
(B) Sorafenib signiﬁcantly inhibited tumor angiogenesis as
indicated by reduced MVD in HCC models, and sorafenib
combined with the anti-Ly6G antibody had a further effect.
*P < .05, **P < .01. Scale bar: 100 mm.
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proinﬂammatory, immunoregulatory, and angiogenic fac-
tors, including hepatocyte growth factor,24 oncostatin M,25
b2-integrins,26 neutrophil elastase,27 matrix metal-
loprotease 9, and vascular endothelial growth factor,28
which can have a paracrine effect on tumor cell biology.
However, these factors also are produced in an autocrine
manner by cancer cells, which also can contribute to cancer
development. In this study, we identiﬁed CCL2 and CCL17,
which are secreted exclusively by TANs, as tumor-
promoting and prognostic factors in HCC.
Several studies have conﬁrmed that neutrophils can
promote growth, migration, and invasion of cancer
cells.24–27,29 However, TAN-derived CCL2 and CCL17 have
no direct effect on HCC cell biology (Supplementary
Figure 12), suggesting that TAN-induced HCC progres-
sion results from modulation of the microenvironment.
CCL2, otherwise referred to as monocyte chemoattractant
protein 1, binds to CCR2 on the surface of monocytes to
regulate their activation and migration. The role of CCL2
in macrophage recruitment to the tumor site has been
shown in multiple tumor types,5 but has not been well
evaluated in HCC, possibly owing to the low CCL2
expression on HCC cells, which was shown by our study.
Although CCL2 also can be produced by some other tumor
microenvironment stromal cells, such as ﬁbroblasts and
macrophages,30,31 we conﬁrmed that in HCC, CCL2 was
secreted abundantly by TANs and recruited macrophages
to inﬁltrate the tumor site. Recently, Mano et al32 reported
that accumulation of intratumoral macrophages was
related to a high neutrophil-to-lymphocyte ratio in pa-
tients with HCC. We conﬁrmed here that a high
neutrophil-to-lymphocyte ratio is correlated with a high
CCL2 expression in tumor tissues (Supplementary
Figure 13), providing a possible explanation of the phe-
nomenon observed by Mano et al.32 CCL17, another C-C
chemokine that has been suggested to be produced by
macrophages and dendritic cells in other cancer
types,33,34 expressed by HCC-associated TANs, recruits
CCR4þ Treg cells, and expression of CCR4 is correlated
with poor prognosis in several cancer types.17 Although
the presence and poor prognosis associated with Treg cell
inﬁltration in HCC has been investigated,35 little is known
about the recruitment of this cell type in HCC. Our study
conﬁrmed that TAN-derived CCL17 is a strong chemo-
attractant for Treg cells, but not CD4þCD25- or CD8þ
lymphocytes (data not shown).
Macrophages and Treg cells both have the ability to
promote tumor progression.2 Our study showed a crucial
role for TANs in recruiting macrophages and Treg cells both
in vitro and in vivo, depletion of which signiﬁcantly atten-
uated the protumor effect of TANs. Thus, TAN-induced tu-
mor promotion is dependent on the recruitment of
macrophages and Treg cells. Moreover, we observed a
further reduction in tumor volume after depletion of TANs,
suggesting that TANs also promote HCC progression
through direct interaction with HCC cells, which currently is
under further exploration.
Figure 6. TAN counts were correlated with the number of intratumoral macrophages and Treg cells, MVD, prognosis, and the
response to sorafenib in HCC patients. (A) Representative HCC tumor samples showing the expression of CD66b, CD68,
Foxp3, and CD34. Scale bar: 100 mm. (B) The number of intratumoral neutrophils, macrophages, and Treg cells was correlated
with MVD in tumor samples. (C) Scatter plot analysis showed a signiﬁcant positive correlation between the number of
intratumoral neutrophils and macrophages or Treg cells. (D) The combined quantity of intratumoral neutrophils, macrophages,
and Treg cells was correlated with MVD in tumor samples. **P < .01. (E) The combined quantity of intratumoral neutrophils,
macrophages, and Treg cells predicted the prognosis of HCC patients. I, intratumoral neutrophils, macrophages, and Treg
cells all low; III, intratumoral neutrophils, macrophages, and Treg cells all high; II, others. (F) Comparison of overall survival
curves between patients with high and low TAN counts who were treated with sorafenib.
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various physiological or pathologic conditions. However,
the factors mediating TAN biology are poorly under-
stood.36 In our study, we observed that nPBNs secreted
more cytokines and chemokines, especially CCL2 and
CCL17, and gained the characteristics of TANs in response
to HCC cells. This result prompted us to investigate the
mechanism by which neutrophils acquire tumor-promoting
functions under tumor microenvironment. We identiﬁed
the PI3K/Akt and p38/MAPK signaling pathways as the
critical pathways mediating the transformation of nPBNs
to TANs in HCC.
Most studies on the mechanisms of sorafenib resistance
have focused primarily on the tumor cells themselves.37,38
However, several studies have uncovered the importance
of the tumor stroma in modulating the effect of anti-
angiogenic therapy.39,40 We found that more TANs, macro-
phages, and Treg cells inﬁltrated the tumor in response to
sorafenib treatment, and the depletion of TANs signiﬁcantly
enhanced the effect of sorafenib in mouse models, sug-
gesting that TANs may promote sorafenib resistance. Clin-
ical data also have indicated that patients with less TAN
inﬁltration were better candidates for sorafenib treatment,
suggesting that TANs could be used as a biomarker for
predicting responsiveness to sorafenib therapy in HCC.
Furthermore, although several studies have reported that
anti-angiogenic therapy-induced hypoxia can promote can-
cer cell invasion and metastasis, these ﬁndings are contex-
tual and debated.41 In our study, we conﬁrmed that
sorafenib-induced hypoxia activates NF-kB signaling to
enhance CXCL5 secretion by HCC cells, which promotes
TANs recruitment. Hypoxia also inhibits TAN apoptosis,
which increases the number of TANs and promotes sor-
afenib resistance.
It should be noted that HCC progression requires the
activation of a tumor- or stromal cell–driven angiogenic
program.42 Neutrophils, macrophages, and Treg cells all
have the ability to promote neovascularization in several
tumor models.18,19 We validated this using both an animal
model and HCC samples. Sorafenib blocks tumor angiogen-
esis by targeting the kinase activity of vascular endothelial
growth factor and platelet-derived growth factor receptors,
but also contributes to TAN accumulation and concomitant
macrophage and Treg cell inﬁltration, which can act as
alternative inducers of angiogenesis in HCC. Although sor-
afenib inhibited angiogenesis in our mouse models, we
observed a further decrease in MVD when sorafenib
treatment was combined with TAN depletion, suggesting
TAN-induced sorafenib resistance is regulated by the pro-
angiogenic effect of TANs.
Collectively, our results showed that TANs mediated the
intratumoral inﬁltration of macrophages and Treg cells by
secreting CCL2 and CCL17, which stimulated neo-
vascularization, enhanced HCC growth and metastasis, and
contributed to sorafenib resistance. We suggest that the
extent of TAN inﬁltration could be used as a biomarker in
HCC for predicting responsiveness to sorafenib therapy and
that TAN depletion could enhance the efﬁcacy of sorafenib
as an anti-HCC therapeutic.Supplementary Material
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Supplementary Materials and Methods
Neutrophil Isolation and Culture
For neutrophil isolation, peripheral blood samples
were collected and fresh liver tumor tissues were sliced
into small pieces and digested in RPMI 1640 supple-
mented with 0.05% collagenase IV (Sigma-Aldrich,
St. Louis, MO), 0.002% DNase I (Roche, Indianapolis, IN),
and 20% fetal bovine serum at 37C for 30 minutes. We
ﬁltered dissociated cells through a 150-mm mesh and then
these cells were centrifuged at 2500 rpm for 20 minutes
with 1 mL cell suspension and 10 mL Ficoll-Hypaque
(Stemcell Technologies, Vancouver, Canada) in a 15-mL
tube. Thereafter, the leukocytes were harvested and
Ly6Gþ cells (mouse neutrophils) or CD66bþ (human
neutrophils) were isolated using the EasySep PE Selection
Kit (Stemcell Technologies, Vancouver, Canada) according
to the manufacturer’s protocol. We conﬁrmed puriﬁcation
of neutrophils via ﬂuorescence-activated cell sorter anal-
ysis with Phycoerythrin (PE)-conjugated anti-Ly6G or
anti-CD66b antibodies, showing a purity of greater than
85% for TANs and greater than 95% for PBNs.
For in vitro activation, nPBNs at 1  106 cells/mL were
treated for 24 hours with conditioned medium from HCC
cells (HepG2, PLC/PRF/5, MHCC97H, HCCLM3, Hepa1-6,
H22) or control conditioned medium. To evaluate the
signaling pathways involved in HCC cell-induced TAN-like
neutrophils, the cells were pretreated with LY294002
(50 mmol/L, PI3K inhibitor) or SB203580 (10 mmol/L, p38
inhibitor) at 37C and 5% CO2 for 1 hour, and subsequently
were exposed to the indicated stimuli.
Macrophage and Treg Cell Isolation
For macrophage isolation, nontumor liver tissues were
harvested, digested, and single-cell suspensions were
collected as described earlier. CD14þ monocytes and mac-
rophages were isolated by magnetic-activated cell sorting
using a direct CD14 Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) in accordance with the manufacturer’s
instructions.
For Treg cell isolation, peripheral blood samples were
collected, Treg cells were isolated by magnetic-activated cell
sorting using the CD4þCD25þ Regulatory T-Cell Isolation
Kit (Miltenyi Biotec) according to the manufacturer’s
instructions.
Monocytes/Macrophages and Treg Cell
Chemotaxis Assay
We assayed cell chemotaxis using a Transwell system
(Corning, Corning, NY) with 5-mm polycarbonate membranes
as described previously.1 CD4þCD25þ Treg cells or CD14þ
monocytes/macrophages suspended in RPMI 1640 contain-
ing 2% fetal bovine serum (1  105 cells/100 mL) were
added to the upper wells and incubated for 24 hours at 37C,
and 5% CO2. Human or mouse recombinant (r)CCL2 or
rCCL17 at various concentration, or supernatants from neu-
trophils derived from different sources, with or without
control Ab (1 mg/mL), anti-CCL2 (1 mg/mL), or anti-CCL17
(1 mg/mL) antibodies were added to the lower chamber. In
some experiments, monocytes/macrophages and Treg cells
were treated with anti-CCR2 (5 mg/mL) or anti-CCR4 (5 mg/
mL). We collected the Treg cells that migrated to the lower
chamber and counted them in Neubauer chambers (Mar-
ienfeld, Lauda-Königshofen, Germany); macrophages that
migrated and attached to the lower surface of the Transwell
membrane were ﬁxed with 4% paraformaldehyde, followed
with 0.5% crystal violet (Sigma-Aldrich) staining and then
subjected to phase-contrast microscopy imaging with a 200
objective, and the negative control comprised cells that
migrated toward RPMI 1640 alone. The chemotactic index
was calculated as the ratio of the number of cells that
migrated to different amboceptor-containing wells divided
by the number of cells that migrated to RPMI 1640 alone.
Neutrophil Chemotaxis Assay
We assayed neutrophil chemotaxis using a Transwell
system (Corning) with 8-mm polycarbonate membranes as
described previously.2 Brieﬂy, supernatants (100 mL)
from hypoxic or normoxic human HCC cells (HepG2, PLC/
PRF/5, MHCC97H, and HCCLM3), or mouse HCC cells (H22
and Hepa1-6), treated with or without shCXCL5,
shCXCL16, shCCL24, sh-interleukin 12a, or control
conditioned medium, were plated into the bottom cham-
bers. Neutrophils suspended in RPMI 1640 containing 2%
fetal bovine serum (1  105 cells/100 mL) were added to
the upper wells and incubated for 2 hours at 37C, 5%
CO2. We collected neutrophils that migrated to the lower
chamber and counted them in Neubauer chambers. The
negative control comprised neutrophils that migrated to-
ward RPMI 1640 alone. The chemotactic index was
calculated as the ratio of the number of neutrophils that
migrated to HCC cell conditioned medium–containing
wells divided by the number of neutrophils that migrated
to RPMI 1640 alone.3
NF-kB–DNA Binding Assays and
Apoptosis Analysis
We prepared nuclear lysates for DNA-binding assays in
accordance with the manufacturer’s instructions (TransAm
kit; ActiveMotif, Carlsbad, CA). We incubated the nuclear
extract with an immobilized oligonucleotide on a 96-well
plate (containing a speciﬁc transcription factor binding site
as indicated), and NF-kB–DNA binding was detected by the
transcription factor enzyme-linked immunosorbent assay.
To quantify the extent of apoptosis, we harvested cells
using trypsin without EDTA and viewed the cells stained
with Annexin V/ﬂuorescein isothiocyanate/propidium io-
dide, in accordance with the manufacturer’s protocol (BD
Biosciences, Rockville, MD).
In Vivo Assays for Tumor Growth and Metastasis
For mouse HCC models, Hepa1-6 and H22 cells alone, or
Hepa1-6 and H22 cells, were co-injected with neutrophils
puriﬁed from tumor tissues of HCC-bearing C57BL/6J or
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BALB/c mice or peripheral blood of non–tumor-bearing
mice into the subcutaneous space of the upper left ﬂank
region of corresponding mice. Cell suspensions consisted of
a 1:10 ratio of the cell mixture (TANs:HCC cells), and, in
these groups, TANs were injected into the tumor at the
indicated dosage biweekly for 4 consecutive weeks from
day 14 after inoculation. We observed the mice over 5
weeks for tumor formation. When the xenografts were
palpable from day 14 after inoculation (approximately 0.5
cm in diameter), 30 mg of control antibody, anti-Ly6G, or
combined anti-CCL2 and anti-CCL17 antibodies were
injected into the tumor. In sorafenib-treatment experi-
ments, a daily oral dose of vehicle solution, 30 mg/kg sor-
afenib, or 30 mg/kg sorafenib was combined with an
injection of 30 mg control antibody or anti-Ly6G into the
tumor twice a week when the xenografts were palpable
from day 14 after inoculation.
We measured tumor size twice weekly with a caliper
and calculated the volume in cm3 as follows: V ¼ ab2/2
(where a and b represent the largest and smallest tumor
diameters measured at necropsy).4 After death, the volume
of each tumor was determined directly. Lungs stably
expressing GFP were analyzed using a LB981 Lumina Im-
aging System (Berthold, Bad Wildbad, Germany), and then
embedded in parafﬁn. We counted the total number of lung
metastases under the microscope as previously described.5
RNA Isolation, Quantitative Reverse-
Transcription PCR, and RT2 Proﬁler PCR Array
We extracted total RNA from cells and frozen tumor
specimens using TRIzol reagent (Invitrogen, Carlsbad, CA)
in accordance with the manufacturer’s instructions. We
measured mRNA expression in cells and tumor tissues via
quantitative reverse-transcription PCR using an ABI7900HT
instrument (Applied Biosystems, Foster City, CA). Quanti-
tative reverse-transcription PCR was performed using a
SYBR PrimeScript reverse-transcription PCR Kit (Takara
Bio, Shiga, Japan) in accordance with the manufacturer’s
instructions. We used glyceraldehyde-3-phosphate dehy-
drogenase as an internal control. The primers used are
listed in Supplementary Table 1. We calculated relative
mRNA levels based on the Ct values and normalized using
glyceraldehyde-3-phosphate dehydrogenase expression,
according to the following equation: 2-DCt (DCt ¼ Ct [target
gene] - Ct [glyceraldehyde-3-phosphate dehydrogenase]).
All experiments were performed in triplicate.
RT2 proﬁler PCR array was performed for screening
neutrophil-derived cytokines/chemokines by using the
Human Cytokines and Chemokines PCR Array (catalogue
number: PAHS-150Z; SABiosciences, Hilden, Germany).
The RT2 proﬁler array was probed by using the Proﬁler
PCR Array System and SYBR green/ﬂuorescein quantita-
tive PCR Master Mix (SABiosciences) in an ABI 7900
sequence analyzer (Applied Biosystems, Carlsbad, CA) in
accordance with the manufacturer’s protocol. Gene
expression was analyzed using RT2 Proﬁler PCR Array
Date Analysis in the dedicated web-based software pack-
age (http://www.superarray.com/pcr/arrayanalysis.php,
SABiosciences, Hilden, Germany), which automatically
performs all 2-DCt–based fold-change calculations from the
speciﬁc uploaded raw threshold cycle data.
Western Blot Analysis, Immunoﬂuorescence
Assay, and Confocal Immunoﬂuorescence
Western blot was performed as previously described.6
Brieﬂy, we generated total cell lysates, and proteins were
separated on a Novex 16% Tricine Gel (Invitrogen) (for
CXCL5, CCL2, and CCL17 proteins) or 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (for other pro-
teins), and then transferred the proteins to polyvinylidene
diﬂuoride membranes. The membranes were washed and
blocked. The primary antibodies and dilutions used are
listed in Supplementary Table 8. Primary antibodies were
applied, followed by horseradish-peroxidase–conjugated
secondary antibodies. Antibody binding was detected by
enhanced chemiluminescence assays.
For immunoﬂuorescence assays, we prepared cells in
the isolated fraction by cytospin (Thermo Fisher, Waltham,
MA) and analyzed them by immunoﬂuorescence. Brieﬂy,
cells were ﬁxed in 4% paraformaldehyde for 15 minutes on
glass slides. Subsequently, the cells were permeabilized
with 0.1% Triton X-100 for 15 minutes at room tempera-
ture, washed with phosphate-buffered saline, and blocked
with phosphate-buffered saline containing 1% (wt/vol)
bovine serum albumin and 0.15% (wt/vol) glycine (bovine
serum albumin buffer) for 1 hour at room temperature.
Cells were treated with primary antibody for 2 hours at
room temperature. A negative control (primary antibody
omitted) was included on every slide. We then washed
the cells with bovine serum albumin buffer and incubated
with 2 mg/mL Alexa Fluor 488/594–conjugated goat
anti-mouse/rabbit antibody (Molecular Probes, Eugene, OR)
for 1 hour at room temperature. After a phosphate-buffered
saline rinse, we counterstained the slices with diamidino
phenylindole and examined them by ﬂuorescence
microscopy (Leica Microsystems Imaging Solutions,
Cambridge, UK).
Enzyme-Linked Immunosorbent Assay
We determined the level of cytokines/chemokines in
cell culture supernatants by using the corresponding
Quantikine human enzyme-linked immunosorbent assay kit
(R&D Systems, Minneapolis, MN) in accordance with the
manufacturer’s instructions. Brieﬂy, we added 100 mL of
sample to each well and incubated the plates for 2.5 hours
at room temperature. The plates were washed and incu-
bated with the conjugate for 2 hours. After washing, we
determined immunoreactivity by adding substrate solution,
and the absorbance was determined using a Microplate
Spectrophotometer (Bio-Rad, Hercules, CA). A curve of the
absorbance vs the concentrations of cytokines/chemokines
in the standard wells was plotted.
Phosphokinase Array Analysis
The phosphokinase array was performed using the hu-
man phosphokinase array blot (catalogue number: ARY003;
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R&D Systems). Protein lysate was incubated with the array
membrane and protein signal was visualized using a
chemiﬂuorescence detection system (Bio-Rad) according to
the manufacturer’s protocol as described previously.7 The
relative intensity of speciﬁc protein expression was deter-
mined using Quantity One (Bio-Rad, Hercules, CA) software.
Tissue Microarray and Immunohistochemistry
Tissue microarrays were constructed as previously
described.8 We took two 1-mm diameter core biopsy spec-
imens from the donor blocks and transferred these to the
recipient parafﬁn block at predeﬁned array positions. We
constructed 3 different tissue microarray blocks including
452 cases in cohort 1 and 380 cases in cohort 2.
Immunohistochemical staining was performed by the
avidin-biotin-peroxidase complex method. Brieﬂy, after
rehydration and microwave antigen retrieval, primary an-
tibodies were applied to slides, incubated at 4C overnight,
and followed with secondary antibody incubation
(GK500705; Gene Tech, Shanghai, China) at 37C for 30
minutes. The primary antibodies and dilutions used are
listed in Supplementary Table 8. Staining was performed
with 3,30-diaminobenzidine tetra hydrochloride and coun-
terstaining was performed with Mayer’s hematoxylin. In all
assays, we included negative control slides with the primary
antibodies omitted.
Evaluation of Immunohistochemical Variables
Immunohistochemical staining was assessed by 3 inde-
pendent investigators who were blinded to patient charac-
teristics, and discrepancies were resolved by consensus.
Under 200 magniﬁcation, photographs of 3 representative
ﬁelds were captured by the Leica QWin Plus v3 software;
identical settings were used for each photograph. For the
CD66b, CCL2, CCL17, CD68, Foxp3, or CD34 staining in tis-
sue microarrays, the number of positive cells or micro-
vessels was calculated in each 1-mm–diameter cylinder and
expressed as the mean value of the triplicates (cells/spot or
microvessels/spot) as described previously.9 Median values
were used as a cut-off value in subsequent analyses unless
speciﬁed. Quantiﬁcation of Ly6G-, F4/80-, Foxp3-positive
cells, or CD34 staining in tumor tissues of xenografts were
calculated as Ly6G-, F4/80-, or Foxp3-positive area/total
area or microvessels/ﬁeld at 200 magniﬁcation in 5 spots
of each section.
Statistical Analysis
Statistical analyses were performed using SPSS (Chicago,
IL) 16.0 for Windows. Data were presented as means ± SD
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of at least 3 independent experiments. Quantitative data
between groups were compared using the Student t test.
Categoric data were analyzed by the chi-square test or the
Fisher exact test. Correlation analysis was performed be-
tween CD66b, CCL17, CCL2, Foxp3, CD68, and CD34. Overall
survival and cumulative recurrence rates were calculated by
the Kaplan–Meier method, and differences were analyzed by
the log-rank test. Univariate and multivariate analyses were
performed using the Cox proportional hazards regression
model. A P value of less than .05 was considered statistically
signiﬁcant.
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Supplementary Figure 1. HCC TANs express high levels of CCL2 and CCL17. (A) CCL2 and CCL17 expression levels in TANs
isolated from HCC patients with or without recurrence were determined by quantitative reverse-transcription PCR. (B) Enzyme-
linked immunosorbent assay for CCL2 and CCL17 in TANs isolated from HCC patients with or without recurrence. (C) CCL2
mRNA and (D) protein expression in nPBNs, HCC cell-activated nPBNs, and HCC cells. (E) CCL17 mRNA and (F) protein
expression in nPBNs, HCC cell-activated nPBNs, and HCC cells. (G and H) Scatter plot of the numbers of CD66bþ neutrophils
and CCL2- or CCL17-positive cells showed a signiﬁcant positive correlation between them. (I) Confocal microscopy showed
co-localization of CCL2 or (J) CCL17 and CD66b immunostaining in TANs and nPBNs. Scale bars: 10 mm. DAPI, 40,6-
diamidino-2-phenylindole.
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Supplementary Figure 2. TAN-derived CCL2 and CCL17 recruit macrophages and Treg cells. (A) Recombinant human CCL2
and CCL17 preferentially recruited macrophages and Treg cells from HCC patients. This response was abrogated by anti-
CCL2 or anti-CCL17 antibodies and was attenuated signiﬁcantly by anti-CCR2 or anti-CCR4 antibodies. **P < .01
compared with control; #P < .05 when compared with control antibody (Ab). (B) nPBNs did not affect the migratory ability of
macrophages or Treg cells. (C) pPBNs had a modest effect on the migratory ability of macrophages and Treg cells, which was
not affected upon anti-CCL2, anti-CCR2, anti-CCL17, or anti-CCR4 antibody treatment. *P < .05 compared with control.
(D and E) The mouse TANs expressed abundant amounts of CCL2 and CCL17, as compared with nPBNs, peripheral blood
neutrophils from tumor-bearing mouse (tPBNs), and HCC cells themselves. (F) Recombinant mouse CCL2 and CCL17 pref-
erentially recruited macrophages and Treg cells from tumor-bearing mice, and this response was abrogated by anti-CCL2 or
anti-CCL17 antibody treatment and was attenuated signiﬁcantly by anti-CCR2 or anti-CCR4 antibody treatment. *P < .05 and
**P < .01 compared with control; #P < .05 when compared with control Ab.
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Supplementary Figure 3. TANs promote intratumoral inﬁltration by macrophages and Treg cells and in a mouse model. (A)
Schematic of mice treated with TANs, anti-Ly6G, or anti-CCL2 and anti-CCL17 in this experiment. (B) Co-injection of HCC
cells with TANs increased the intratumoral inﬁltration of F4/80þ macrophages and Treg cells, as well as MVD. Intratumoral
injection with an anti-Ly6G antibody completely abrogated TAN inﬁltration, signiﬁcantly reduced the inﬁltration of F4/80þ
macrophages and Treg cells induced by TANs, and suppressed neovascularization in mouse models. Furthermore, anti-CCL2
and anti-CCL17 antibodies reduced intratumoral inﬁltration of F4/80þ macrophages and Treg cells and suppressed neo-
vascularization while having no effect on the number of TANs. **P < .01 compared with control; #P < .05 and ##P < .01
compared with TANs þ control antibody (Ab).
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Supplementary Figure 4. Labeling of the phosphokinase assay.
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Supplementary Figure 5. HCC cells educate nPBNs to gain TAN-like characteristics through PI3K/Akt and p38/MAPK
signaling. (A) Western blot showed that mouse HCC cells activated PI3K/Akt and p38/MAPK signaling in mouse nPBNs. (B)
Western blot and (C) enzyme-linked immunosorbent assay showed that blocking both the PI3K/Akt and p38/MAPK pathways
by using LY294002 and SB203580 completely inhibited the increased secretion of CCL2 and CCL17 by H22 and Hepa1-6
cells. CM, conditioned medium; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LY,
LY294002; SB, SB203580.
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Supplementary Figure 6. Sorafenib treatment increased the intratumoral inﬁltration of neutrophils. (A) Sorafenib treatment
increased CCL2 and CCL17 secretion levels in tumor tissues of HCC-bearing mice. **P < .01. (B) CXCL5 expression was
increased by hypoxic conditions in 2 mouse HCC cell lines, H22 and Hepa1-6 (left); CXCL5 knockdown abolished hypoxia-
induced neutrophil migration (right). *P < .05, **P < .01. (C) Western blot showed increased HIF1a and p65 nuclear
accumulation under hypoxia, and (D) enhanced NF-kB DNA binding activity by enzyme-linked immunosorbent assay. *P < .05,
**P < .01. (E) Western blot for CXCL5 in hypoxia-treated mouse HCC cells pretransfected with shRNA-GFP, shRNA-HIF1a, or
shRNA-p65, or pretreated with dimethyl sulfoxide (DMSO), BAY-117082, or JSH-23. (F) Scatter plot diagram based on
immunohistochemistry analysis shows a signiﬁcant positive correlation between HIF1a expression and TAN inﬁltration in
cancerous tissues. (G) Immunohistochemistry showed increased nuclear expression of HIF1a and p65 in sorafenib-treated
HCC-bearing mice (left) or patients (right), accompanied by increased CXCL5 expression. Scale bars: 50 mm. (H) Hypoxia
inhibited the apoptosis of nPBNs, pPBNs, and TANs (Con) in mouse H22 (left) and Hepa1-6 (right) cell-bearing models as
measured by AV/PI staining and Western blot for caspase-3. TANs (Con), TANs from HCC model mice that did not receive
sorafenib treatment; TANs (Sora), TANs from HCC model mice that received sorafenib treatment. *P < .05, **P < .01. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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Supplementary Figure 7. Sorafenib directly inhibited p38/MAPK signaling in nPBNs. (A) Sorafenib treatment caused a
decrease in the phosphorylation levels of P38, (B) but exerted no effect on phosphorylation of Akt in human nPBNs and mouse
nPBNs. (C–H) p38/MAPK and PI3K/Akt signaling was activated signiﬁcantly in response to different HCC cells, even after
sorafenib treatment. CM, conditioned medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Supplementary Figure 8. Sorafenib treatment contributes to TAN accumulation and concomitant intratumoral macrophage
and Treg cell inﬁltration in mouse HCC models derived from (A) H22 and (B) Hepa1-6. Ab, antibody.
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Supplementary Figure 9. TAN counts were correlated with the number of intratumoral M2 macrophages. (A) Expression of
CD66b, CD68, CD163, and CD206 in representative HCC tumor samples. Scale bar: 100 mm. (B and C) Scatter plot analysis
showed that most intratumoral CD68þ macrophages are of the M2 subtype (CD68þ or CD206þ), and the number of M2
macrophages was correlated strongly with the number of intratumoral neutrophils.
Supplementary Figure 10. Kaplan–Meier survival curve of HCC patients with lower (<12 per view of ﬁeld, n ¼ 226 ) and higher
TAN counts (12 per view of ﬁeld, n ¼ 226), or with lower (<105 per view of ﬁeld, n ¼ 226) and higher intratumoral macrophage
counts (105 per view of ﬁeld, n ¼ 226), or with lower (<14 per view of ﬁeld, n ¼ 223), and higher intratumoral Treg cell counts
(14 per view of ﬁeld, n ¼ 229).
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Supplementary Figure 11. TAN inﬁltration was correlated with macrophage and Treg cell inﬁltration, MVD, and prognosis,
which was validated in an independent cohort of 380 HCC patients. (A) Scatter plot of CD66bþ neutrophils and CCL2- or
CCL17-positive cells showed a signiﬁcant positive correlation between them. (B) Scatter plot showed a signiﬁcant positive
correlation between intratumoral neutrophils and macrophages or Treg cells. (C) The number of intratumoral neutrophils,
macrophages, and Treg cells was correlated with MVD in tumor samples. (D) Kaplan–Meier survival curve of HCC patients with
lower (<11 per view of ﬁeld) and higher TAN counts (11 per view of ﬁeld), or with lower (<8 per view of ﬁeld) and higher CCL2-
positive TAN counts (8 per view of ﬁeld), or with lower (<9 per view of ﬁeld) and higher CCL17-positive TAN counts (9 per
view of ﬁeld). (E) Kaplan–Meier survival curve of patients with lower (<102 per view of ﬁeld) and higher intratumoral macro-
phages counts (102 per view of ﬁeld), or with lower (<13 per view of ﬁeld) and higher intratumoral Treg cell counts (13 per
view of ﬁeld). (F) The combined number of intratumoral neutrophils, macrophages, and Treg cells predicted the prognosis of
HCC patients. I, intratumoral neutrophils, macrophages and Treg cells all low; III, intratumoral neutrophils, macrophages and
Treg cells all high; II, others.
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Supplementary Figure 12. CCL2 and CCL17 had no direct effects on HCC cell biology. (A) HCC cell proliferation, as
measured by the CCK8 assay, did not show a signiﬁcant difference between different concentrations of CCL2 and CCL17
treatment and control cells. (B) Cell monolayers were wounded and monitored at 0 and 24 hours for wound channel closure.
The cleared area was measured and plotted as the percentage of the original area at 0 hours. (C) Invasive behavior was
evaluated by Transwell Matrigel (BD Biosciences, San Jose, CA) invasion assays. (D) annexin V/propidium iodide (AV/PI)
staining showed apoptosis of HCC cells after treatment with different concentrations of CCL2 and CCL17.
Supplementary Figure 13. In samples from patients with a high neutrophil-to-lymphocyte ratio (NLR), more CCL2þ cells
inﬁltrated the tumor tissues in both (A) cohort 1 and (B) cohort 2.
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